AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 42 min read$MDLN

Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up

Medline (MDLN) reported a 39.4% drop in Q3 net income to $195M, despite a 10.4% sales increase to $7.856B. Adjusted EBITDA rose 11.8% to $960M. The company reaffirmed its FY26 Adj. EBITDA guidance of $3.3B-$3.4B. Shares rose 8.54% in pre-market trading.

Original reporting
rttnews.com
Published Nov 4, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$MDLNBullishHigh
01

Why it matters

The earnings release provides fresh data that moved the stock 8% higher pre‑market, offering a clear trading trigger.

02

Market read

The earnings surprise and guidance reaffirmation create immediate buying interest, making the story highly relevant for short‑term traders.

03

What to watch

One‑time non‑controlling interest gain of $123 M inflates net income; core earnings may be weaker than headline numbers imply.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Medline, a Nasdaq‑listed medical‑surgical products provider, released its Q3 2026 earnings, showing a profit drop but a sales increase and reaffirmed FY26 EBITDA guidance.

Company-level read

Ticker impact

$MDLNBullishHigh confidence
Context

Medline reported Q3 profit decline, reaffirmed FY26 adjusted EBITDA guidance, and shares jumped 8.5% pre‑market.

Expected impact

upward pressure as investors price in reaffirmed EBITDA outlook and pre‑market rally.

Evidence & confidence

The earnings release includes new numbers and guidance, and the stock is already up 8% pre‑market, indicating fresh buying interest.

Market effects

Sector

Medical‑surgical supply sector may see modest upside as Medline's reaffirmed guidance supports industry demand.

Regional

U.S. equity markets, particularly Nasdaq healthcare segment.

Global

Limited to investors tracking U.S. healthcare distributors.

Counterpoint

What could challenge this read

Profit fell sharply and net income halved, suggesting underlying margin pressure that could temper the rally.

Key entities

  • company
    Medline, Inc.

    Provider of medical‑surgical products and supply chain solutions, ticker MDLN.

Read at source← All news

StoryMedline raises full‑year organic sales outlook, launches $1 billion share buyback

Also covered by

5 outlets

Related articles

NOV 4
Low

Medline Q3 2026 slides: sales rise 10%, shares jump 15% on guidance

Medline Industries reported Q3 2026 net sales of $7.9B, up 10.4%, and adjusted EBITDA of $960M, up 11.8%. Shares rose 15.58% on raised guidance and a $1B share repurchase program. Organic sales grew 10.5%, with segment growth varying. Higher costs and lower-margin distribution impacted margins. The company expects continued growth and improved market share.

investing.com2 min
NOV 4
$MDLNHighAI 8/10

Medline: Q3 Earnings Snapshot

Medline Inc. (MDLN) reported Q3 earnings of $195 million, or 22 cents per share, beating analyst estimates of 34 cents per share. Adjusted earnings were 44 cents per share. Revenue was $7.86 billion, exceeding forecasts of $7.69 billion, according to Zacks Investment Research.

finance.yahoo.com2 min
NOV 4
$MDLNMedAI 8/10

Medline Q3 Sales Rise 10.4% to $7.9 Billion; Net Income Falls 1.2%

Medline reported Q3 2026 net sales of $7.856B, up 10.4% YoY, but net income fell 1.2% to $318M. Adjusted EBITDA rose 11.8% to $960M. The company raised its full-year organic sales growth outlook to 10.0%-10.5% and reaffirmed Adjusted EBITDA guidance of $3.3B-$3.4B. Medline also announced a $1B share repurchase program and prepaid $750M of its 2033 term loan.

tradingview.com2 min
NOV 4
$MDLNHighAI 9/10

Medline Reports Third Quarter and Nine Months 2026 Results

Medline Inc. (MDLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. November 4, 2026 Medline Reports Third Quarter and Nine Months 2026 Results • Third quarter net sales of $7.9 billion, an increase of 10.4% • Third quarter net income of $318 million, a decrease of 1.2% • Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8% • Nin

SEC EDGAR 8-K2 min